SERPINE1 and hypertensive disorder: These results align with earlier studies demonstrating the therapeutic potential of PAI-1 inhibitors in mitigating metabolic dysfunction (19, 23, 69, 70), fibrosis (21), hypertension (67), and muscle atrophy (71).